Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christof Reusch"'
Autor:
Linda Pudelko, Frank Jaehrling, Christof Reusch, Santiago Viteri, Christopher Stroh, Nina Linde, Michael P. Sanderson, Doreen Musch, Catherine Jorand Lebrun, Marina Keil, Christina Esdar, Andree Blaukat, Rafael Rosell, Karl Maria Schumacher, Niki Karachaliou
Publikováno v:
iScience, Vol 23, Iss 12, Pp 101832- (2020)
Summary: Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skippi
Externí odkaz:
https://doaj.org/article/271642f4d25a4e358fc48d0799b55381
Autor:
Manja, Friese-Hamim, Anderson, Clark, Dominique, Perrin, Lindsey, Crowley, Christof, Reusch, Olga, Bogatyrova, Hong, Zhang, Timothy, Crandall, Jing, Lin, Jianguo, Ma, David, Bachner, Jürgen, Schmidt, Martin, Schaefer, Christopher, Stroh
Publikováno v:
Lung Cancer. 163:77-86
Central nervous system-penetrant therapies with intracranial efficacy against non-small cell lung cancer (NSCLC) brain metastases are urgently needed. We report preclinical studies investigating brain penetration and intracranial activity of the MET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6251c962bc1d7af754da95a0bf7ce932
https://doi.org/10.1016/j.lungcan.2021.11.020
https://doi.org/10.1016/j.lungcan.2021.11.020
Autor:
Andree Blaukat, Frank Jaehrling, Niki Karachaliou, Santiago Viteri, Christopher Stroh, Doreen Musch, Karl Maria Schumacher, Rafael Rosell, Linda Pudelko, Catherine Jorand Lebrun, Marina Keil, Nina Linde, Christina Esdar, Michael P. Sanderson, Christof Reusch
Publikováno v:
iScience, Vol 23, Iss 12, Pp 101832-(2020)
iScience
iScience
Summary Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skippin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40626997dea117d3ecadbc911aa3ffc
http://www.sciencedirect.com/science/article/pii/S2589004220310294
http://www.sciencedirect.com/science/article/pii/S2589004220310294
Autor:
Claudia Wilm, Christopher Stroh, Jing Lin, Anderson Clark, Martin Schaefer, David Bachner, Christof Reusch, Jürgen Schmidt, Hong Zhang, Olga Bogatyrova, Lindsey Crowley, Jianguo Ma, Timothy Crandall, Manja Friese-Hamim
Publikováno v:
Cancer Research. 80:3407-3407
Background Patients with advanced non-small cell lung cancer (NSCLC) harboring oncogenic MET alterations, such as MET exon 14 skipping or MET amplification (MET amp), benefit from MET tyrosine kinase inhibitor (TKI) treatment. Brain metastases are co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1a49b499dff7e3e850973a53ea1fac4
https://doi.org/10.1158/1538-7445.am2020-3407
https://doi.org/10.1158/1538-7445.am2020-3407
Publikováno v:
Cancer Research. 70:LB-316
Background: Therapeutic antibodies can attack tumor cells by functionally interfering with the target and/or by employing immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1527b7f9594c8bed50c85b8c6a1134a
https://doi.org/10.1158/1538-7445.am10-lb-316
https://doi.org/10.1158/1538-7445.am10-lb-316